Insight in taste alterations during treatment with protein kinase inhibitors

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

The role of Protein Kinase Inhibitors (PKI) in the treatment of various types of cancer is increasingly prominent. Their clinical application is accompanied by the development of side effects, among which patient-reported taste alterations. These alterations are missed frequently, but impair nutritional intake, are associated with weight loss and often result in significant morbidity, especially in the context of chronic administration. Accurate reporting of taste alterations is hampered by lack of modules for symptom objectification and inadequate understanding on the underlying mechanisms. In this review we initially describe the physiology of taste and smell and the mechanism of action of PKIs. We proceed to summarize taste related side effects as reported in major clinical trials and describe possible causal factors. Lastly, an in-depth analysis is given on potential molecular pathways responsible for the PKI-induced taste alterations. Objectification of patient-reported symptoms and universal reporting, along with a better understanding of the underlying mechanisms, will lead to early recognition and optimized treatment, ultimately improving patient adherence and quality of life.

Original languageEnglish
Pages (from-to)125-134
Number of pages10
JournalEuropean Journal of Cancer
Volume86
DOIs
Publication statusPublished - 1 Nov 2017

Cite this

@article{931cd7045eab4961804ee50182f96e05,
title = "Insight in taste alterations during treatment with protein kinase inhibitors",
abstract = "The role of Protein Kinase Inhibitors (PKI) in the treatment of various types of cancer is increasingly prominent. Their clinical application is accompanied by the development of side effects, among which patient-reported taste alterations. These alterations are missed frequently, but impair nutritional intake, are associated with weight loss and often result in significant morbidity, especially in the context of chronic administration. Accurate reporting of taste alterations is hampered by lack of modules for symptom objectification and inadequate understanding on the underlying mechanisms. In this review we initially describe the physiology of taste and smell and the mechanism of action of PKIs. We proceed to summarize taste related side effects as reported in major clinical trials and describe possible causal factors. Lastly, an in-depth analysis is given on potential molecular pathways responsible for the PKI-induced taste alterations. Objectification of patient-reported symptoms and universal reporting, along with a better understanding of the underlying mechanisms, will lead to early recognition and optimized treatment, ultimately improving patient adherence and quality of life.",
keywords = "Dysgeusia, Dysosmia, Mucositis, Oral adverse events, Protein kinase inhibitor, Smell, Taste",
author = "{van der Werf}, A. and M. Rovithi and Langius, {J. A.E.} and {de van der Schueren}, {M. A.E.} and Verheul, {H. M.W.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.ejca.2017.09.006",
language = "English",
volume = "86",
pages = "125--134",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Pergamon",

}

TY - JOUR

T1 - Insight in taste alterations during treatment with protein kinase inhibitors

AU - van der Werf, A.

AU - Rovithi, M.

AU - Langius, J. A.E.

AU - de van der Schueren, M. A.E.

AU - Verheul, H. M.W.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - The role of Protein Kinase Inhibitors (PKI) in the treatment of various types of cancer is increasingly prominent. Their clinical application is accompanied by the development of side effects, among which patient-reported taste alterations. These alterations are missed frequently, but impair nutritional intake, are associated with weight loss and often result in significant morbidity, especially in the context of chronic administration. Accurate reporting of taste alterations is hampered by lack of modules for symptom objectification and inadequate understanding on the underlying mechanisms. In this review we initially describe the physiology of taste and smell and the mechanism of action of PKIs. We proceed to summarize taste related side effects as reported in major clinical trials and describe possible causal factors. Lastly, an in-depth analysis is given on potential molecular pathways responsible for the PKI-induced taste alterations. Objectification of patient-reported symptoms and universal reporting, along with a better understanding of the underlying mechanisms, will lead to early recognition and optimized treatment, ultimately improving patient adherence and quality of life.

AB - The role of Protein Kinase Inhibitors (PKI) in the treatment of various types of cancer is increasingly prominent. Their clinical application is accompanied by the development of side effects, among which patient-reported taste alterations. These alterations are missed frequently, but impair nutritional intake, are associated with weight loss and often result in significant morbidity, especially in the context of chronic administration. Accurate reporting of taste alterations is hampered by lack of modules for symptom objectification and inadequate understanding on the underlying mechanisms. In this review we initially describe the physiology of taste and smell and the mechanism of action of PKIs. We proceed to summarize taste related side effects as reported in major clinical trials and describe possible causal factors. Lastly, an in-depth analysis is given on potential molecular pathways responsible for the PKI-induced taste alterations. Objectification of patient-reported symptoms and universal reporting, along with a better understanding of the underlying mechanisms, will lead to early recognition and optimized treatment, ultimately improving patient adherence and quality of life.

KW - Dysgeusia

KW - Dysosmia

KW - Mucositis

KW - Oral adverse events

KW - Protein kinase inhibitor

KW - Smell

KW - Taste

UR - http://www.scopus.com/inward/record.url?scp=85030465653&partnerID=8YFLogxK

U2 - 10.1016/j.ejca.2017.09.006

DO - 10.1016/j.ejca.2017.09.006

M3 - Review article

VL - 86

SP - 125

EP - 134

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

ER -